Dual antiplatelet therapy with clopidogrel and aspirin increases mortality in 4T1 metastatic breast cancer-bearing mice by inducing vascular mimicry in primary tumour
Platelet inhibition has been considered an effective strategy for combating cancer metastasis and compromising disease malignancy although recent clinical data provided evidence that long-term platelet inhibition might increase incidence of cancer deaths in initially cancer-free patients. In the pre...
Saved in:
| Published in: | Oncotarget Vol. 9; no. 25; p. 17810 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
03.04.2018
|
| Subjects: | |
| ISSN: | 1949-2553, 1949-2553 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Platelet inhibition has been considered an effective strategy for combating cancer metastasis and compromising disease malignancy although recent clinical data provided evidence that long-term platelet inhibition might increase incidence of cancer deaths in initially cancer-free patients. In the present study we demonstrated that dual anti-platelet therapy based on aspirin and clopidogrel (ASA+Cl), a routine regiment in cardiovascular patients, when given to cancer-bearing mice injected orthotopically with 4T1 breast cancer cells, promoted progression of the disease and reduced mice survival in association with induction of vascular mimicry (VM) in primary tumour. In contrast, treatment with ASA+Cl or platelet depletion did reduce pulmonary metastasis in mice, if 4T1 cells were injected intravenously. In conclusion, distinct platelet-dependent mechanisms inhibited by ASA+Cl treatment promoted cancer malignancy and VM in the presence of primary tumour and afforded protection against pulmonary metastasis in the absence of primary tumour. In view of our data, long-term inhibition of platelet function by dual anti-platelet therapy (ASA+Cl) might pose a hazard when applied to a patient with undiagnosed and untreated malignant cancer prone to undergo VM. |
|---|---|
| AbstractList | Platelet inhibition has been considered an effective strategy for combating cancer metastasis and compromising disease malignancy although recent clinical data provided evidence that long-term platelet inhibition might increase incidence of cancer deaths in initially cancer-free patients. In the present study we demonstrated that dual anti-platelet therapy based on aspirin and clopidogrel (ASA+Cl), a routine regiment in cardiovascular patients, when given to cancer-bearing mice injected orthotopically with 4T1 breast cancer cells, promoted progression of the disease and reduced mice survival in association with induction of vascular mimicry (VM) in primary tumour. In contrast, treatment with ASA+Cl or platelet depletion did reduce pulmonary metastasis in mice, if 4T1 cells were injected intravenously. In conclusion, distinct platelet-dependent mechanisms inhibited by ASA+Cl treatment promoted cancer malignancy and VM in the presence of primary tumour and afforded protection against pulmonary metastasis in the absence of primary tumour. In view of our data, long-term inhibition of platelet function by dual anti-platelet therapy (ASA+Cl) might pose a hazard when applied to a patient with undiagnosed and untreated malignant cancer prone to undergo VM. Platelet inhibition has been considered an effective strategy for combating cancer metastasis and compromising disease malignancy although recent clinical data provided evidence that long-term platelet inhibition might increase incidence of cancer deaths in initially cancer-free patients. In the present study we demonstrated that dual anti-platelet therapy based on aspirin and clopidogrel (ASA+Cl), a routine regiment in cardiovascular patients, when given to cancer-bearing mice injected orthotopically with 4T1 breast cancer cells, promoted progression of the disease and reduced mice survival in association with induction of vascular mimicry (VM) in primary tumour. In contrast, treatment with ASA+Cl or platelet depletion did reduce pulmonary metastasis in mice, if 4T1 cells were injected intravenously. In conclusion, distinct platelet-dependent mechanisms inhibited by ASA+Cl treatment promoted cancer malignancy and VM in the presence of primary tumour and afforded protection against pulmonary metastasis in the absence of primary tumour. In view of our data, long-term inhibition of platelet function by dual anti-platelet therapy (ASA+Cl) might pose a hazard when applied to a patient with undiagnosed and untreated malignant cancer prone to undergo VM.Platelet inhibition has been considered an effective strategy for combating cancer metastasis and compromising disease malignancy although recent clinical data provided evidence that long-term platelet inhibition might increase incidence of cancer deaths in initially cancer-free patients. In the present study we demonstrated that dual anti-platelet therapy based on aspirin and clopidogrel (ASA+Cl), a routine regiment in cardiovascular patients, when given to cancer-bearing mice injected orthotopically with 4T1 breast cancer cells, promoted progression of the disease and reduced mice survival in association with induction of vascular mimicry (VM) in primary tumour. In contrast, treatment with ASA+Cl or platelet depletion did reduce pulmonary metastasis in mice, if 4T1 cells were injected intravenously. In conclusion, distinct platelet-dependent mechanisms inhibited by ASA+Cl treatment promoted cancer malignancy and VM in the presence of primary tumour and afforded protection against pulmonary metastasis in the absence of primary tumour. In view of our data, long-term inhibition of platelet function by dual anti-platelet therapy (ASA+Cl) might pose a hazard when applied to a patient with undiagnosed and untreated malignant cancer prone to undergo VM. |
| Author | Jasztal, Agnieszka Stojak, Marta Przyborowski, Kamil Chlopicki, Stefan Kieronska, Anna Derszniak, Katarzyna Zakrzewska, Agnieszka Selmi, Anna Wandzel, Krystyna Proniewski, Bartosz Wietrzyk, Joanna Buczek, Elzbieta Wojcik, Tomasz Smeda, Marta Watala, Cezary Kaczor, Dawid |
| Author_xml | – sequence: 1 givenname: Marta surname: Smeda fullname: Smeda, Marta organization: Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, Bobrzynskiego 14, Krakow 30-348, Poland – sequence: 2 givenname: Anna surname: Kieronska fullname: Kieronska, Anna organization: Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, Bobrzynskiego 14, Krakow 30-348, Poland – sequence: 3 givenname: Bartosz surname: Proniewski fullname: Proniewski, Bartosz organization: Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, Bobrzynskiego 14, Krakow 30-348, Poland – sequence: 4 givenname: Agnieszka surname: Jasztal fullname: Jasztal, Agnieszka organization: Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, Bobrzynskiego 14, Krakow 30-348, Poland – sequence: 5 givenname: Anna surname: Selmi fullname: Selmi, Anna organization: Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, Bobrzynskiego 14, Krakow 30-348, Poland – sequence: 6 givenname: Krystyna surname: Wandzel fullname: Wandzel, Krystyna organization: Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, Bobrzynskiego 14, Krakow 30-348, Poland – sequence: 7 givenname: Agnieszka surname: Zakrzewska fullname: Zakrzewska, Agnieszka organization: Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, Bobrzynskiego 14, Krakow 30-348, Poland – sequence: 8 givenname: Tomasz surname: Wojcik fullname: Wojcik, Tomasz organization: Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, Bobrzynskiego 14, Krakow 30-348, Poland – sequence: 9 givenname: Kamil surname: Przyborowski fullname: Przyborowski, Kamil organization: Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, Bobrzynskiego 14, Krakow 30-348, Poland – sequence: 10 givenname: Katarzyna surname: Derszniak fullname: Derszniak, Katarzyna organization: Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, Bobrzynskiego 14, Krakow 30-348, Poland – sequence: 11 givenname: Marta surname: Stojak fullname: Stojak, Marta organization: Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, Bobrzynskiego 14, Krakow 30-348, Poland – sequence: 12 givenname: Dawid surname: Kaczor fullname: Kaczor, Dawid organization: Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, Bobrzynskiego 14, Krakow 30-348, Poland – sequence: 13 givenname: Elzbieta surname: Buczek fullname: Buczek, Elzbieta organization: Jagiellonian Centre for Experimental Therapeutics, Jagiellonian University, Bobrzynskiego 14, Krakow 30-348, Poland – sequence: 14 givenname: Cezary surname: Watala fullname: Watala, Cezary organization: Department of Haemostasis and Haemostatic Disorders, Medical University of Lodz, Kosciuszki 4, Lodz 90-419, Poland – sequence: 15 givenname: Joanna surname: Wietrzyk fullname: Wietrzyk, Joanna organization: Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Department of Experimental Oncology, Rudolfa Weigla 4, Wroclaw 53-114, Poland – sequence: 16 givenname: Stefan surname: Chlopicki fullname: Chlopicki, Stefan organization: Chair of Pharmacology, Jagiellonian University, Medical College, Grzegorzecka 16, Krakow 31-531, Poland |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29707148$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkMtOwzAQRS1UBKX0A9ggL9mk2I7zWiLeUiU2ZV1N7Elr5MTBdkD9Ib6TFIrEbObqzpmr0ZyRSec6JOSCswUv81Rcu065CH6DcSFkWfEjMuWVrBKRZenknz4l8xDe2FiZLEpRnZBTURWs4LKckq-7ASyFLpreQkSLkcYteuh39NPELVXW9Ua7jcc9pSmE3njTUdMpjxAw0Nb5CNbE3ehRueK0xQghQjSK1nsmUgWdQp_UCOPqhrZGIa33vB7U3viAoAYLfpyMM_-T1HvTwijj0LrBn5PjBmzA-aHPyOvD_er2KVm-PD7f3iwTlXLJE620QCzzBljNoalVkYlc541kAptCqDrTNaajZqVmiIWQTaFVlgqpGDQpihm5-s3tvXsfMMR1a4JCa6FDN4S1YKkoKpmnbEQvD-hQt6jXh4PXf78V3_lhhcY |
| CitedBy_id | crossref_primary_10_3390_ph15121532 crossref_primary_10_1002_glia_23997 crossref_primary_10_1016_j_bcp_2020_113886 crossref_primary_10_3389_fonc_2021_764119 crossref_primary_10_1093_ehjcvp_pvz003 crossref_primary_10_1177_00037028211025540 crossref_primary_10_1038_s41420_025_02428_6 crossref_primary_10_2217_bmm_2019_0514 crossref_primary_10_1007_s10585_018_9924_8 crossref_primary_10_1017_S1431927620001324 crossref_primary_10_1093_jnci_djy205 crossref_primary_10_1182_blood_2020005710 crossref_primary_10_1007_s10555_024_10222_6 crossref_primary_10_3390_ijms22084153 crossref_primary_10_1016_j_bbadis_2018_08_022 crossref_primary_10_1002_jbio_201900067 crossref_primary_10_1002_jbio_201800345 crossref_primary_10_1186_s12935_025_03877_w crossref_primary_10_1093_micmic_ozad032 crossref_primary_10_1186_s12885_018_4445_z crossref_primary_10_1186_s13058_018_1013_z crossref_primary_10_1186_s13058_018_1075_y crossref_primary_10_1016_j_apsb_2024_04_034 crossref_primary_10_3390_molecules25010236 crossref_primary_10_1007_s10585_019_10009_y crossref_primary_10_1002_ijc_34343 crossref_primary_10_1007_s11302_024_10027_w crossref_primary_10_1016_j_bbcan_2025_189276 |
| ContentType | Journal Article |
| DBID | NPM 7X8 |
| DOI | 10.18632/oncotarget.24891 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| EISSN | 1949-2553 |
| ExternalDocumentID | 29707148 |
| Genre | Journal Article |
| GroupedDBID | --- 53G ADBBV ADRAZ AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL DIK FRJ GX1 HYE KQ8 M48 M~E NPM OK1 PGMZT RPM 7X8 |
| ID | FETCH-LOGICAL-c3141-dcd2ee86fa0b1afbc7526d6f402ef72cb5dbe32ef08d0ee724f7dc5324c0af3e2 |
| IEDL.DBID | 7X8 |
| ISSN | 1949-2553 |
| IngestDate | Thu Jul 10 18:44:13 EDT 2025 Thu Jan 02 22:24:34 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 25 |
| Keywords | clopidogrel platelet inhibition aspirin mouse breast cancer vascular mimicry |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3141-dcd2ee86fa0b1afbc7526d6f402ef72cb5dbe32ef08d0ee724f7dc5324c0af3e2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://doi.org/10.18632/oncotarget.24891 |
| PMID | 29707148 |
| PQID | 2032794630 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2032794630 pubmed_primary_29707148 |
| PublicationCentury | 2000 |
| PublicationDate | 20180403 |
| PublicationDateYYYYMMDD | 2018-04-03 |
| PublicationDate_xml | – month: 4 year: 2018 text: 20180403 day: 3 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Oncotarget |
| PublicationTitleAlternate | Oncotarget |
| PublicationYear | 2018 |
| SSID | ssj0000547829 |
| Score | 2.341762 |
| Snippet | Platelet inhibition has been considered an effective strategy for combating cancer metastasis and compromising disease malignancy although recent clinical data... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 17810 |
| Title | Dual antiplatelet therapy with clopidogrel and aspirin increases mortality in 4T1 metastatic breast cancer-bearing mice by inducing vascular mimicry in primary tumour |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29707148 https://www.proquest.com/docview/2032794630 |
| Volume | 9 |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8QwFA7qePDigtu4EcFrtE235CSiDh50mMMocxvSJIWC047TVvAP-Tt9L-3oSRC8lJK8lkfW7-2EXKA1TRppmUqlYCHPIqaMjBmA60gp5UfGxXG_PCbDoZhM5KhTuFWdW-XyTHQHtSk16sivsNI3JkMPvOv5G8OqUWhd7UporJJeAFAGXbqSifjWsXiYrMoVKgNRXTJAz0Fn2BRxwK9KTH_g_K0veSik_zvIdJfNYOu_bG6TzQ5m0pt2XeyQFVvsks-7BtpgKPP5K0BMmDHahl99UFTHUo3RU6YECRypDFVohc8LmhcILStb0ZkD6wDcoY2GY5_ObK0wJinXNEWammpcRguWwg6CW5FitXuaIr1pNDYsXV-hB_oW7k_zNuUFrZsZML5Hngf349sH1tVpYDrwQ58Zbbi1Is6Ul_oqS3US8djEGYimNku4TiOT2gDePWE8axMeZonREUA57akssHyfrBVlYQ8JjVQoeGg1CFU6BGKltGd1ImRsRCyl6ZPz5bBPYR-gcUMVtmyq6c_A98lBO3fTjvsplwnGaYmjP3x9TDYAEwnnnBOckF4Gp4A9Jev6vc6rxZlbYPAcjp6-ABv24bI |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dual+antiplatelet+therapy+with+clopidogrel+and+aspirin+increases+mortality+in+4T1+metastatic+breast+cancer-bearing+mice+by+inducing+vascular+mimicry+in+primary+tumour&rft.jtitle=Oncotarget&rft.au=Smeda%2C+Marta&rft.au=Kieronska%2C+Anna&rft.au=Proniewski%2C+Bartosz&rft.au=Jasztal%2C+Agnieszka&rft.date=2018-04-03&rft.eissn=1949-2553&rft.volume=9&rft.issue=25&rft.spage=17810&rft_id=info:doi/10.18632%2Foncotarget.24891&rft_id=info%3Apmid%2F29707148&rft_id=info%3Apmid%2F29707148&rft.externalDocID=29707148 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1949-2553&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1949-2553&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1949-2553&client=summon |